麻豆视频

Tin Tin Su of CU Boulder and Antonio Jimeno of the CU School of Medicine say acceleration-initiative funds will help speed a promising, developed-in-Colorado cancer therapy to patients

After working eight years on a new way to attack some cancers, a pair of听听researchers are closer to their goal of bringing their therapy to patients鈥攁s one of nine research endeavors receiving funding from the听听(础础滨).

The project is led jointly by听Tin Tin Su, co-leader of the cancer center鈥檚听 and professor of molecular, cellular and developmental biology at the 麻豆视频, and , a co-leader of the CU Cancer Center鈥檚听听and professor in the听'蝉听.

Jimeno says it鈥檚 significant that the AAI award is for a potential cancer therapy 鈥渢hat was discovered in Colorado and will use Colorado funds from a Colorado donor to help Colorado cancer patients.鈥�

He adds: 鈥淗ere at the CU Cancer Center, we can get things done really well and really quickly, provided we have the focus and the resources. And this grant provides both.鈥�

Their work involves the use of a synthetic small molecule called SVC112, which has been shown to effectively target cancer stem cells in听, the main focus of Jimeno鈥檚听.

Cancer stem cells produce cells that make up most of a tumor鈥檚 bulk. They often are resistant to traditional therapies such as radiation and chemotherapy and can recover from treatment to produce more tumor cells. The U.S. Food & Drug Administration has approved the use of protein synthesis inhibitors that slow or stop cancer cell growth, but they can be toxic to healthy cells as well as cancer cells.

SVC112 was originally synthesized by SuviCa, Inc., a Boulder-based biotechnology company co-founded by Su. It鈥檚 based on the chemical bouvardin, found in the firecracker bush,听Bouvardia ternifolia, a red-flowering plant that grows in the Southwest and Mexico.

The discovery in Su鈥檚 research lab at CU Boulder of bouvardin鈥檚 remarkable ability to prevent regeneration of tissues in the fruit fly led to the current studies.

Previous research听by Jimeno, Su, and others showed that SVC112 can keep cancer stem cells from manufacturing more tumor cells. The pre-clinical research indicated that SVC112 can be more effective than the FDA-approved protein synthesis inhibitor听homoharringtonin (HHT), and with less toxicity, while also increasing the effects of radiation treatment.

鈥淚t鈥檚 effective in ways that other drugs are not,鈥� Su says. 鈥淭his compound has shown efficacy in squamous head and neck cancer, in salivary gland cancer, colorectal cancer, and leukemia models. This is very exciting, because it proves the biologic point that multiple tumor types rely on the same mechanisms, the same proteins, to become invasive, to grow and to metastasize.鈥�

Su points out that SVC112 passed three reviews to be approved to receive milestone-based support from the National Cancer Institute鈥檚 (NCI)听听in 2023, providing resources for SVC112鈥檚 development. NCI is part of the National Institutes of Health.

Jimeno says that the five-year AAI grant will help fund the arduous next steps in developing SVC112. First, the researchers will conduct pre-clinical experiments leading to an investigational new drug filing to the FDA within two years. Next, he says, plans call for a first-in-human Phase 1a听听in cancer patients 鈥渢o determine the safe, optimal way of delivering this to humans, employing all the clinical-trials capabilities of our university, including the听,鈥� followed by a Phase 1b trial.

Cancers to be targeted in later stages of the clinical trials may change based on early results, if the researchers see patients with certain cancers responding especially well, Jimeno says.

The AAI recipients were announced in January by CU School of Medicine Dean John J. Reilly, Jr., MD, during his annual听.

听is a writer for the Anschutz School of Medicine, which published a .

Top image:听Bouvardia ternifolia, or firecracker bush (Photo: U.S. Forest Service)

Did you enjoy this article?听听Passionate about molecular, cellular and developmental biology?听Show your support.

听